BeOne Medicines

BeOne Medicines (formerly known as BeiGene) is a massive, highly disruptive global biopharmaceutical company fundamentally focused on developing innovative and accessible oncology treatments to eradicate cancer. Originally founded in 2010 by biotechnology entrepreneur John V. Oyler and cancer scientist Xiaodong Wang, the company recently rebranded and redomiciled its global headquarters to Basel, Switzerland, while maintaining massive operational hubs in Cambridge, Massachusetts, and Beijing, China. Under the hood, BeOne operates a staggering research and development ecosystem, driving an expansive pipeline of targeted small-molecule therapies, immune checkpoint inhibitors, and novel antibody-drug conjugates. Their primary target audience spans oncologists, clinical researchers, and millions of cancer patients worldwide who desperately need more affordable, high-efficacy medicines like BRUKINSA and TEVIMBRA. What sets BeOne Medicines apart in the fiercely competitive pharmaceutical landscape is its sheer scale and unprecedented speed—employing nearly 12,000 people across six continents and running over 175 clinical trials globally, effectively uniting the global community to change the status quo of global cancer care.